{"contentid": 488364, "importid": NaN, "name": "Novel immuno-oncology approach shows promise", "introduction": "A licensing deal between XOMA Corporation and Affimed Therapeutics is starting to bear fruit, with progress in three innate cell engager (ICE) programs.", "content": "<p>A licensing deal between XOMA Corporation (Nasdaq: XOMA) and Affimed Therapeutics (Nasdaq: AFMD) is starting to bear fruit, with progress in three innate cell engager (ICE) programs.</p>\n<p>The programs in question are being progressed by Affimed, a German clinical-stage biotech, using ICE technology developed by XOMA.</p>\n<p>They are the result of a 2006 agreement, under which Affimed in-licensed certain XOMA technologies to further its research and discovery efforts.</p>\n<p>The Californian company is eligible to receive undisclosed payments on future commercial sales of each of the three ICE molecules and any pre-loaded NK cells containing the ICE molecules.</p>\n<p>In addition, XOMA is eligible to receive an undisclosed milestone for each program should marketing approval be achieved.</p>\n<p>Chief executive Jim Neal said: &ldquo;It&rsquo;s always exciting to see XOMA&rsquo;s legacy technology license agreements mature into clinical-stage drug candidates that may generate economic benefits for XOMA in the future.&rdquo;</p>\n<p>&ldquo;We&rsquo;re delighted to add AFM13, AFM24, and an undisclosed clinical-stage partnered asset to XOMA&rsquo;s portfolio,&rdquo; he added.</p>\n<h2>AFM13 and AFM24</h2>\n<p>A first-in-class CD30/CD16A ICE, AFM13 is generated from Affimed&rsquo;s ROCK platform, and has Orphan Drug designation from the US regulator.</p>\n<p>Affimed is currently studying AFM13 in combination with cord blood-derived allogeneic natural killer cells, together with the MD Anderson Cancer Center in Texas, USA.</p>\n<p>An EGFR- and CD16A-binding ICE also generated from the ROCK platform, AFM24 uses the cytotoxic potential of the innate immune system to kill EGFR-positive cancer cells.</p>", "date": "2021-04-16 12:24:00", "meta_title": NaN, "meta_keywords": "XOMA, Affimed, programs, innate, immuno-oncology, shows, promise, approach, licensing, deal, Corporation, Therapeutics, engager, cell, progress, fruit, bea", "meta_description": "A licensing deal between XOMA Corporation and Affimed Therapeutics is starting to bear fruit, with progress in three innate cell engager (ICE) programs.", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-16 10:11:46", "updated": "2021-04-16 12:24:29", "access": NaN, "url": "https://www.thepharmaletter.com/article/novel-immuno-oncology-approach-shows-promise", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "xoma_large.png", "image2id": "xoma_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Immuno-oncology", "topic_tag": "Deals, Financial, Licensing, Research", "geography_tag": "Germany, USA", "company_tag": "Affimed Therapeutics, XOMA Corporation", "drug_tag": "AFM13, AFM24", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-16 12:24:00"}